Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The National Task Force for Covid-19 in India has denied inclusion of Biocon’s itolizumab in its clinical management protocols for the disease.
Earlier this month, the drug received emergency use authorisation from the Drugs Controller General of India (DCGI) to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients with Covid-19.
The drug is an anti-CD6 IgG1 monoclonal antibody introduced in India in 2013 under the brand name ALZUMAb to treat chronic plaque psoriasis.